SCHEMBL6465257

SCHEMBL6465257

O=C(/C=C/c1cccc(/C=C/C(=O)c2cccc(F)c2)c1)NO

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 12/20 0.74
HDAC8 Q9BY41 10/20 0.74
HDAC6 Q9UBN7 10/20 0.74
HDAC3 O15379 10/20 0.74
HDAC1 Q13547 10/20 0.74
HDAC11 Q96DB2 9/20 0.74
HDAC2 Q92769 9/20 0.74
HDAC7 Q8WUI4 8/20 0.74
HDAC10 Q969S8 8/20 0.74
HDAC9 Q9UKV0 8/20 0.74
HDAC5 Q9UQL6 8/20 0.74
RELA Q04206 2/20 0.61
MEF2D Q14814 3/20 0.57
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1320084 0.87 HDAC8 (0.62) HDAC4HDAC8HDAC6HDAC3HDAC1
SCHEMBL1320083 0.87 HDAC8 (0.62) HDAC4HDAC8HDAC6HDAC3HDAC1
SCHEMBL12425750 0.87 HDAC4 (0.67) HDAC4HDAC8HDAC6HDAC3HDAC1
SCHEMBL3836781 0.87 RELA (0.68) HDAC8HDAC6HDAC11RELA
SCHEMBL14244352 0.87 HDAC4 (0.67) HDAC4HDAC8HDAC6HDAC3HDAC1
SCHEMBL3836785 0.87 RELA (0.68) HDAC8HDAC6HDAC11RELA
SCHEMBL6369565 0.85 HDAC1 (1.00) HDAC4HDAC8HDAC6HDAC3HDAC1
SCHEMBL1321341 0.85 HDAC8 (0.60) HDAC4HDAC8HDAC6HDAC3HDAC1
SCHEMBL1321339 0.85 HDAC8 (0.60) HDAC4HDAC8HDAC6HDAC3HDAC1
SCHEMBL8987205 0.85 MAOB (0.68) HDAC4HDAC8HDAC6HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115867-A1 NEW CLASS OF HISTONE DEACETYLASE INHIBITORS DAC S.R.L. (IT) 2012-05-10 US disclosed
EP-2197854-B1 A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS DAC SRL (IT) 2011-08-10 EP disclosed
US-20100305123-A1 CLASS OF HISTONE DEACETYLASE INHIBITORS DAC S.R.L. (IT) 2010-12-02 US disclosed
US-20100305123-A1 CLASS OF HISTONE DEACETYLASE INHIBITORS DAC S.R.L. (IT) 2010-12-02 US disclosed
EP-2033956-A1 A new class of histone deacetylase inhibitors DAC S.r.l. (IT) 2009-03-11 EP disclosed
WO-2009027395-A1 A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS DAC S.R.L. (IT) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115867-A1 NEW CLASS OF HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC5, HDAC1 HDAC4 13/4885HDAC8 14/4885HDAC6 15/4885
US-20100305123-A1 CLASS OF HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC5 HDAC4 13/4885HDAC8 12/4885HDAC6 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.